Antibody Sequence & Patent Scout

Start from a known target. The platform first recovers antibody/antigen sequences, SEQ IDs, clones, and source evidence; epitope disclosure is evaluated after sequence recovery.

Live API sources

Hits in last run

Query variants

Sequence leads

Needs-key APIs

How to use

1. Enter the target

Fill in target, aliases, and disease / therapeutic context. State detection antibodies / IHC / ELISA / flow as exclusions up front.

2. AI-first auto sweep

Click Run scout; the platform recalls sequences, SEQ IDs, patents, and public evidence first, then you add evidence and correct the read.

3. Confirm the sequence first

Prioritise VH/VL/CDR, full FASTA, SEQ ID, clone, and antigen sequence; keep even a bare sequence lead.

4. Then read the epitope

A useful sequence comes first; an epitope may be disclosed, undisclosed, or given only as competition / blocking, which needs later interpretation.

5. Hand off downstream

A sequence unlocks structure prediction, interface scoring, and wet-lab validation; an epitope claim then feeds challenge / design-around.

Target setup

Target

Aliases

Therapeutic / exclusion context

AI-first Scout

UniProt Antigen

Resolves the antigen: sequence, structure links.

Lens Patent API

Runs after token configuration.

Europe PMC

Literature & bio-patent index.

NCBI Patent Seq

Patent sequence records.

IEDB B-cell

Known B-cell epitope evidence.

RCSB PDB

Experimental antigen / complex structures.

AlphaFold Structure

Predicted antigen structure when no experimental one exists.

Click Run scout to trigger first-pass sequence/SEQ ID recall, evidence structuring, and table generation. Missing epitope is not an empty result; a sequence lead is already useful.

Sequence-first evidence table

Target	Sequence / SEQ ID	Therapeutic Antibody	Epitope Disclosure (optional)	Sourcing Basis
Run scout first; the table will be generated automatically.

Query pack

(FCRL5 OR FcRH5 OR CD307 OR FCRH5) antibody therapeutic patent

(FCRL5 OR FcRH5 OR CD307 OR FCRH5) monoclonal antibody sequence SEQ ID VH VL CDR

(FCRL5 OR FcRH5 OR CD307 OR FCRH5) epitope claim competition antibody blocking

(FCRL5 OR FcRH5 OR CD307 OR FCRH5) CAR-T scFv antigen binding domain

(FCRL5 OR FcRH5 OR CD307 OR FCRH5) diagnostic IHC ELISA flow clone

Evidence notes

Patent families / claims

Sequence evidence

Epitope evidence

Decision / next action

Read-out checklist

Does a therapeutic antibody / CAR binder clearly appear?

Should diagnostic antibody, IHC, ELISA, or flow cytometry be excluded?

Is a full VH/VL, CDR, or SEQ ID provided?

Is a clone number given, and can the sequence be traced back?

Is an epitope residue, domain, competition antibody, or blocking pattern specified?

Is the claim a sequence, epitope, composition, or method-of-treatment claim?

Note

This produces an evidence map and R&D judgement, not an FTO or legal opinion. A real challenge / design-around strategy needs patent counsel to confirm against a claim chart.